Europe Approves World’s First Moderna Flu‑COVID Combo Vaccine While US Holds Back

TheThe European Commission has authorized Moderna's mRNA-1083, known as mCOMBRIAX, making it the first combination vaccine globally to target both influenza and COVID-19. This decision follows a positive review from a key European Medicines Agency committee in February.

The vaccine combines components of Moderna's established COVID-19 vaccine with an investigational influenza vaccine, mRNA-1010. While approved for use in Europe, the vaccine, developed in the United States, awaits regulatory decisions there.

Authorization of mCOMBRIAX rests on data from a Phase III clinical trial involving approximately 4,000 adults. This randomized controlled trial (RCT) evaluated two age groups.

For adults aged 50 to 64, the vaccine was compared against a standard flu vaccine. In participants aged 65 and older, it was compared against a high-dose flu vaccine.

Results showed mCOMBRIAX generated statistically significant higher immune responses against common influenza strains (A/H1N1, A/H3N2, B/Victoria) and SARS-CoV-2 compared to the respective comparator vaccines. The trial reported no new safety concerns or adverse events.

Moderna CEO Stéphane Bancel stated the combination shot simplifies immunization for adults, especially high-risk individuals. This single dose approach offers protection against two significant respiratory viruses.

This European authorization provides a new option for individuals seeking protection against both flu and COVID-19 with a single injection. For healthcare systems, it offers a potential path to streamline vaccination efforts and improve compliance rates.

The vaccine's design targets two major respiratory threats simultaneously. This aims to reduce the burden of separate vaccination appointments.

The United States developed this vaccine. Observers will watch for the outcomes of ongoing regulatory reviews and potential future availability in the US market.